voyag trial result pt pt
messag updat model estim follow
morn announc voyag trial miss link reduc
pt remov kit gist estim maintain
buy rate compani remain well-posit area includ system
mastocytosi pdgfra gist ret tumor maintain buy increas
pt believ ripretinib could potenti captur entir
us opportun next-gener inhibitor kit-driven gist
remov kit gist estim ayvakit model reduc pt
 maintain buy despit voyag setback believ compani
remain fundament well-posit multipl key indic meaning pipelin
event mileston throughout ayvakit remain approv therapi
pdgfra gist compel efficaci pois read updat top-lin result
phase navig phase ii pathfind support potenti snda
advanc system mastocytosi sm prior data similarli compel
ret inhibitor pralsetinib recent updat promis top-lin result nsclc link
mtc link kol feedback highlight pralsetinib higher complet
respons rate rel competitor selpercatinib rais possibl slightli
potent molecul see oncolog day nsclc kol takeaway recal also
recent file ind next-gen pdgfra inhibitor possess similar on-
target potenc ayvakit without penetr see corpor updat note
 day note ind file two gener egfr inhibitor may occur
ind potenti first-in-class inhibitor rog-ch collabor may
occur thereaft base estim price target valuat
consist ayvakit pdgfra gist ayvakit system mastocytosi
ret inhibitor pralsetinib balanc expect cash year
pois captur entir kit gist opportun next-gener
inhibitor rais pt maintain buy without viabl next-gener
competitor model captur entir opportun select kit inhibitor
annual us patient gist annual us patient po
intrigu gist top-lin result expect peak share
gist potenti off-label use po depend intrigu result
hypothet bull case scenario intrigu succe po could
potenti see fairli valu per share ripretinib repres view
beyond commerci opportun head multipl pipelin event
includ ripretinib phase updat could de-risk opportun data
updat inhibitor rebastinib inhibitor well ind file
autophagi ulk kinas inhibitor
page analyst certif import disclosur
valuat valu per share use dcf base valuat method valuat includ
probability-adjust cash flow deriv compani pipelin includ avapritinib use discount rate
termin growth rate appli termin year post-assum gener entri lead pipelin candid
risk risk valuat includ regulatori commerci setback potenti emerg
new competitor lower product sale expect
valuat price target per share base probability-adjust estim gist net cash
balanc sheet year use discount cash flow analysi use wacc termin growth rate
appli termin year post-assum gener entri
risk risk rate valuat includ regulatori commerci setback potenti emerg new
competitor lower product sale expect cash flow-neg compani may also engag financ activ
dilut exist sharehold
page analyst certif import disclosur
total cost expens
interest incom net
loss extinguish debt
incom tax
page analyst certif import disclosur
total cost expens
interest incom net
loss extinguish debt
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
